Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Solid Tumors 1Sarcoma, Alveolar Soft Part 1Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1Muscle-invasive Bladder Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Rituximab 6venetoclax 5Bendamustine Hydrochloride 5obinutuzumab 3acalabrutinib 3zanubrutinib 2pirtobrutinib 2idelalisib 2ibrutinib 2Chlorambucil 2umbralisib 1ublituximab 1ofatumumab 1fludarabine phosphate 1duvelisib 1atezolizumab 1Pharmacogenomic Testing 1Cyclophosphamide 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Leukemia, Lymphocytic, Chronic, B-Cell × atezolizumab × Clear all
NCT02500407 2025-09-12

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Genentech, Inc.

Phase 1/2 Completed
713 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡